Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson, Ira M; Lawitz, Eric J; Gane, Edward J; Willems, Bernard E; Ruane, Peter J; Nahass, Ronald G.; Borgia, Sergio M; Shafran, Stephen D; Workowski, Kimberly A.; Pearlman, Brian L; Hyland, Robert H; Stamm, Luisa M; Svarovskaia, Evguenia S; Dvory-Sobol, Hadas; Zhu, Yanni; Subramanian, G Mani; Brainard, Diana M.; McHutchison, John G; Bräu, Norbert; Berg, Thomas; Agarwal, Kosh; Bhandari, Bal Raj; Davis, Mitchell G.; Feld, Jordan J.; Dore, Gregory J.; Stedman, Catherine A M; Thompson, Alexander J V; Asselah, Tarik; Roberts, Stuart K.; Foster, Graham R.

doi:10.1053/j.gastro.2017.03.047

Record: found
Abstract: found
Article: not found

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Author(s): Ira M Jacobson, Eric Lawitz, Edward J Gane, Bernard E Willems, Peter J Ruane, Ronald G Nahass, Sergio M Borgia, Stephen D Shafran, Kimberly A Workowski, Brian Pearlman, Robert H Hyland, Luisa M Stamm, Evguenia Svarovskaia, Hadas Dvory-Sobol, Yanni Zhu, G Mani Subramanian, Diana M Brainard, John G McHutchison, Norbert Bräu, Thomas Berg, Kosh Agarwal, Bal Raj Bhandari, Mitchell Davis, Jordan J Feld, Gregory J Dore, Catherine A M Stedman, Alexander J Thompson, Tarik Asselah, Stuart K Roberts, Graham R Foster

Publication date: 2017-07-01

Journal: Gastroenterology

Publisher: Elsevier BV

Keywords: Direct-Acting Antiviral Agent, Comparison, Clinical Trial, Shortened Duration Therapy

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).